← Eichor
Condition: Kras G12D Mutation Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Kras G12D Mutation

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Phase 1/Phase 2 · 27 location(s) · Institut de Recherches Internationales Servier · NCT05786924IX001 TCR-T In the Treatment of Advanced Pancreatic Cancer and Colorectal Cancer Induced by KRAS Mutations
Phase 1 · 1 location(s) · Shanghai Pudong Hospital · NCT06487377A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
Phase 1 · 34 location(s) · Incyte Corporation · NCT06179160Phase I Study of HRS-6093 in Participants With Advanced Solid Tumors Harboring KRAS G12D Mutations
Phase 1 · 2 location(s) · Jiangsu HengRui Medicine Co., Ltd. · NCT07134998A Study to Investigate the Safety and Efficacy of KQB548 in Participants With Advanced Solid Malignancies
Phase 1 · 13 location(s) · Kumquat Biosciences Inc. · NCT07207707Imatinib and Trametinib for KRAS-mutated Solid Tumor
Phase 1 · 1 location(s) · China Medical University Hospital · NCT06962254A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
Phase 1/Phase 2 · 1 location(s) · Blueprint Medicines Corporation · NCT07629960A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
Phase 2 · 19 location(s) · Verastem, Inc. · NCT07644559QTX3034 in Patients With KRAS G12D Mutation
Phase 1 · 14 location(s) · Quanta Therapeutics · NCT06227377A Study of GFH375 in Patients With Advanced Solid Tumors With KRAS G12D Mutations
Phase 1/Phase 2 · 20 location(s) · Genfleet Therapeutics (Shanghai) Inc. · NCT06500676A Study of RNK08954 in Subjects With Advanced Solid Tumors With KRAS ((Kirsten Rat Sarcoma) G12D Mutation
Phase 1/Phase 2 · 6 location(s) · Ranok Therapeutics (Hangzhou) Co., Ltd. · NCT06667544A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patien
Phase 1/Phase 2 · 1 location(s) · Shenzhen Ionova Life Sciences Co., Ltd. · NCT07610798A Phase I Clinical Study of QLC1101 in Patients With Advanced Solid Tumors
Phase 1 · 5 location(s) · Qilu Pharmaceutical Co., Ltd. · NCT06403735Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Phase 1/Phase 2 · 93 location(s) · Revolution Medicines, Inc. · NCT06162221A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation
Phase 1/Phase 2 · 19 location(s) · Tyligand Pharmaceuticals (Suzhou) Limited · NCT06385925A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mut
Phase 3 · 5 location(s) · Astellas Pharma Global Development, Inc. · NCT07566052A Phase I/IIa Study of JAB-23E73 in Patients With Advanced Solid Tumors Harboring KRAS Gene Alteration
Phase 1/Phase 2 · 32 location(s) · Jacobio Pharmaceuticals Co., Ltd. · NCT06959615A Study of PT0253 in Participants With KRAS G12D Mutated Advanced Solid Tumors
Phase 1 · 7 location(s) · PAQ Therapeutics, Inc. · NCT06797336A Phase II Study of HRS-4642 Combined With AG (Nab-paclitaxel and Gemcitabine) as Conversion Therapy for Locally Advance
Phase 2 · 1 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT07438106HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D Mutation
Phase 2 · 2 location(s) · Zhejiang University · NCT07240766Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
Phase 1 · 18 location(s) · AstraZeneca · NCT06218914JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
Phase 1/Phase 2 · 4 location(s) · Jacobio Pharmaceuticals Co., Ltd. · NCT06973564A Study of ASP3082 in Adults With Advanced Solid Tumors
Phase 1 · 62 location(s) · Astellas Pharma Inc · NCT05382559A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancre
Phase 3 · 215 location(s) · Incyte Corporation · NCT07522073A Phase 1 Study of D3S-003 as Monotherapy in Participants With Advanced Solid Tumors With a KRAS p.G12D Mutation.
Phase 1 · 5 location(s) · D3 Bio (Wuxi) Co., Ltd · NCT07456046A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer
Phase 2 · 8 location(s) · Verastem, Inc. · NCT07659795A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients
Phase 1 · 41 location(s) · Genentech, Inc. · NCT06619587To Evaluate the Safety and Efficacy of RNK08954 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma.
Phase 2 · 2 location(s) · Ranok Therapeutics (Hangzhou) Co., Ltd. · NCT07303465Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatmen
Phase 3 · 4 location(s) · Revolution Medicines, Inc. · NCT07621718A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations
Phase 2 · 2 location(s) · Murdoch Childrens Research Institute · NCT05983159
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.